Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Delricht Research

Neither a doctor nor a teaching hospital

Research payments

$27,776,007

20,715 payments

Through program year 2025, Delricht Research is reported as receiving $27,776,007 in research payments, across 20,715 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $13,067,194 1,835
2024 Research $1,073,301 1,095
2023 Research $7,973,342 9,806
2022 Research $4,989,156 7,589
2021 Research $287,492 283
2020 Research $253,781 77
2019 Research $131,741 30

Breakdown

Who paid Research payments · program years 2019–2025
  1. Moderna TX, Inc. $23,083,876 16,695 payments
  2. Incyte Corporation $2,588,782 2,116 payments
  3. Biofrontera Bioscience GmbH $426,330 17 payments
  4. Ucb SA $306,119 75 payments
  5. Novartis Pharmaceuticals Corporation $230,107 6 payments
  6. AbbVie, Inc. $193,969 41 payments
  7. Amgen Inc. $190,032 14 payments
  8. Biofrontera Inc. $124,901 38 payments
  9. Alnylam Pharmaceuticals Inc. $85,432 1,449 payments
  10. Ipsen Innovation $84,041 47 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $4,322,116 6,883 payments
  2. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $4,271,831 355 payments
  3. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $3,768,725 5,340 payments
  4. A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations $3,075,757 77 payments
  5. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $3,014,439 356 payments
  6. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $2,940,550 3,395 payments
  7. A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 $1,644,843 270 payments
  8. A Phase 2, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema $488,163 308 payments
  9. Ala-Acv-Ct014 $426,330 17 payments
  10. A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $363,259 537 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record